Skip to main content
OpenTrials
Completed

NCT Number: NCT05662033

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.

Additionally, the study will include Part 3 (bioavailability and food effect cohort) to assess the relative oral bioavailability between test formulation and oral suspension (reference formulation) as well as the effect of a high fat high calorie (HFHC) meal on the PK of AZD6793 test formulation, in comparison to fasting conditions, after a single oral dose of AZD6793 in healthy participants.

Part 4 of the study (Chronic Obstructive Pulmonary Disease [COPD] cohort) is intended to evaluate AZD6793 safety, tolerability, and PK profile for the first time in participants with moderate to severe COPD.

Part 1 (SAD), Part 2 (MAD) and Part 3 (Bioavailability and food effect cohort) have been completed. Although it was planned that 5 cohorts would be included in Part 1, only 4 cohorts (32 participants) were included. Part 3 of the study was concluded with 13 healthy participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Inflammatory Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Research Site, Harrow, United Kingdom

Loading trial locations.

About this study

Parts 1, 2, and 3 were conducted in a single center and Part 4 is conducted in 2 centers.

Part 1 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2)
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before IMP administration [Day 1]) until at least 72 hours after IMP administration. Participants will then be discharged on Day 4 if in good health and after all samples have been collected. Depending on the emerging data, the length of the stay at the Clinical Unit may be changed.
  • A Follow-up Visit within 6 ± 1 days after the IMP dose (this visit may be done later if indicated, for example, if emerging PK data indicates a longer AZD6793 half-life than was predicted).

Part 2 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before first IMP administration [Day 1]) until Day 10. participants will receive a single dose of IMP in the morning on Day 1. After a washout of at least 48 hours (depending on PK data from Part 1), participants will be dosed twice daily (12 hours apart) from Day 3 through Day 7. Participants will receive the last dose of IMP in the morning of Day 8. Participants will then be discharged on Day 10 if in good health and after all samples have been collected.
  • A Follow-up Visit within 6 ± 1 days after the last IMP dose (this visit may be done later if indicated, for example, if emerging PK data indicates a longer AZD6793 half-life than was predicted).

Part 3 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 until Day 3. Participants will be randomised on Day 1 of Visit 3 to one of 3 treatment sequences and will receive AZD6793 on Day 1 of each treatment period. Dose administration will be separated by a washout period of at least 3 days from the previous IMP dose of each treatment period.
  • A Follow-up Visit within 6 ± 1 days after the last IMP dose

Part 4 of the study will comprise:

  • A Screening Period of maximum 35 days (Day -35 to -2)
  • A Treatment Period of up to 28 days (at least 26 days) of dosing with AZD6793 or placebo. The participants will be admitted to the Clinical Unit on Day -1 and will receive single dose of AZD6793 or placebo on Day 1 and discharged from the Clinical Unit in the evening on Day 1 (12 hours post-dose).
  • A Follow--up Visit 6 ± 2 days after the last IMP dose

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

Parts 1,2 and 3:

  • Healthy male or female participants aged 18 to 55 years with suitable veins for cannulation or repeated venepuncture
  • Females must have a negative pregnancy test must not be lactating and must be either (a) non-childbearing potential, confirmed by post-menopausal defined as amenorrhea for at least 12 months; documentation of irreversible surgical sterilisation or (b) childbearing potential, i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile (Must agree to use, with their partner, an approved method of highly effective contraception).
  • Male participants and their female partners of childbearing potential must be willing to use highly effective contraception measures and male participants must refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the last dose of IMP.
  • Have a BMI between 18 and 30 kg/m2 inclusive and weigh at least 50 kg, at the Screening Visit.

Part 4:

  • Male and/or female participants, who have moderate to severe COPD, and aged 40 through 80 years inclusive.
  • BMI between 18 to 44.9 kg/m2 at Screening
  • Documented history of COPD with a post-bronchodilator FEV1/FVC <0.70 and a post-bronchodilator FEV1 ≥ 30% and < 80% predicted at Screening
  • Documented stable inhaled treatment regimen of dual therapy or triple therapy for ≥ 3 months prior to Screening.
  • Clinically stable and free from an Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the opinion of the Investigator for at least 35 days prior to Day 1
  • Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of :
  • Non-childbearing potential confirmed at screening
  • If considered of childbearing potential, must agree to use with their partner an approved method of highly effective contraception.
  • Male participants and their female partners of childbearing potential must be willing to use highly effective contraception measures and must refrain from donating sperm or fathering a child from first day of dosing until 3 months after last IMP dose.

Main Exclusion Criteria:

Parts 1,2 and 3:

  • History or presence of gastrointestinal, hepatic, renal, pancreatic disease or acute disease in these organs.
  • History of chronic haematologic disease.
  • Diagnosis or history of immunodeficiency or increased susceptibility to severe infection, or a clinically significant infection
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Positive or indeterminate QuantiFERON® Tuberculosis (TB) test at screening.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results
  • Any positive result on Screening for serum Hepatitis B surface antigen (HBsAg), hepatitis C antibody and Human immunodeficiency virus (HIV).
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting Electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG.
  • Known or suspected history of alcohol and drug abuse in the last year.
  • Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months.
  • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6793.
  • Excessive intake of caffeine containing drinks or food
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Parts 2 and 3 only: Participants who have previously received AZD6793.

Part 4:

  • Concurrent enrolment in another clinical study involving an investigational treatment
  • Participants unable to perform reproducible spirometry according to American Thoracic Society/ European Respiratory Society [ATS/ERS] criteria at Screening
  • Any active medical condition or other reason (at Screening, Day -1, and pre-dose) that would interfere with evaluation of the investigational product or interpretation of participant safety or study results, any other clinically relevant abnormal findings on physical examination or laboratory testing at Screening
  • Positive or indeterminate QuantiFERON® TB test at Screening. Indeterminate results may be repeated during Screening.
  • Major surgery within 8 weeks prior to Screening
  • Donation of blood or blood products in excess of 500 mL within 3 months prior to Screening
  • History or current diagnosis of cancer, history of an underlying condition that predisposes the participant to infections, known history of severe reaction to any medication, history of allogeneic bone marrow transplant and history of viral, bacterial or fungal infections within 4 weeks prior to randomisation
  • Receiving any immunotherapy or immunosuppressive therapy other than corticosteroids within 6 months of randomisation
  • Participants taking metformin during Screening or at any time during the study
  • Any participant with active hepatitis or Human immunodeficiency virus (HIV)
  • History or presence of vitiligo or significant (in the opinion of the Investigator) skin depigmentation for any cause including drugs
  • History of clinically significant chronic/active haematology disease

Treatment and study plan

AZD6793

Drug

AZD6793 will be administered orally

Placebo

Drug

Placebo will be administered orally

Primary outcomes

  1. Part 1 (SAD): Number of participants with adverse events

    Time frame: From screening up to Follow up visit (Day 6±1)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  2. Part 2 (MAD): Number of participants with adverse events

    Time frame: From screening up to Follow up visit (Day 14±1)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  3. Part 1 (SAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Time frame: From screening, Treatment Day 1 to Day 4 up to Follow up visit (Day 6±1)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  4. Part 2 (MAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  5. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Time frame: From screening, Treatment Day -1 to Day 4 up to Follow up visit (Day 6±1)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  6. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  7. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)

    Time frame: Day 1 to Day 3

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  8. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)

    Time frame: Day 1 to Day 3, Day 5, Day 8 to Day 10

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  9. Part 1 (SAD): Number of participants with abnormal findings in Telemetry

    Time frame: Day -1 to Day 3

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  10. Part 2 (MAD): Number of participants with abnormal findings in Telemetry

    Time frame: Day -1 to Day 2 and Day 8 to Day 10

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  11. Part 1 (SAD): Number of participants with abnormal findings in Physical examinations

    Time frame: From screening, Treatment Day -1 to 4 and follow up visit

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  12. Part 2 (MAD): Number of participants with abnormal findings in Physical examinations

    Time frame: From screening, Treatment Day -1 to 10 and follow up visit

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  13. Part 1 (SAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)

    Time frame: From screening, Treatment Day -1, Day 2, Day 4 and Follow up visit (Day 6±1)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

  14. Part 2 (MAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

  15. Part 3 (Bioavailability): Maximum observed plasma (peak) drug concentration [Cmax]

    Time frame: Day 1 to Day 3

    Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.

  16. Part 3 (Bioavailability): Area under plasma concentration-time curve from zero to infinity [AUCinf]

    Time frame: Day 1 to Day 3

    Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.

  17. Part 3 (Food effect): Cmax of AZD6793

    Time frame: Day 1 to Day 3

    Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.

  18. Part 3 (Food effect): AUCinf of AZD6793

    Time frame: Day 1 to Day 3

    Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.

  19. Part 4 (COPD): Number of participants with adverse events

    Time frame: From screening up to Follow up visit (Day 34±2)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

  20. Part 4 (COPD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Time frame: From screening up to Follow up visit (Day 34±2)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

  21. Part 4 (COPD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Time frame: From screening up to Follow up visit (Day 34±2)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

  22. Part 4 (COPD): Number of participants with abnormal findings in Physical examinations

    Time frame: From screening, Treatment Day -1, 1, 14, 28 and follow up visit (34±2)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

  23. Part 4 (COPD): Number of participants with abnormal findings in Laboratory assessments (haematology, clinical chemistry, coagulation tests, and urinalysis)

    Time frame: From screening up to Follow up visit (Day 34±2)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

Secondary outcomes

  1. Part 1 (SAD): Maximum observed plasma (peak) drug concentration (Cmax)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  2. Part 1 (SAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  3. Part 1 (SAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  4. Part 1 (SAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  5. Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  6. Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  7. Part 1 (SAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  8. Part 1 (SAD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  9. Part 1 (SAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  10. Part 1 (SAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  11. Part 1 (SAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  12. Part 1 (SAD): Area under the plasma concentration time curve from time zero extrapolated to infinity divided by the dose administered (Dose normalised AUCinf)

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  13. Part 1 (SAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax).

    Time frame: Day 1 to Day 3

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  14. Part 2 (MAD): Maximum observed plasma (peak) drug concentration (Cmax)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  15. Part 2 (MAD): Concentration at the end of the dosing interval (Ctrough)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  16. Part 2 (MAD): Temporal change parameter (TCP) assessed in urine

    Time frame: Day 1 and Day 8

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

  17. Part 2 (MAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  18. Part 2 (MAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  19. Part 2 (MAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  20. Part 2 (MAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  21. Part 2 (MAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  22. Part 2 (MAD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  23. Part 2 (MAD): Area under plasma concentration time curve in the dosing interval t (AUCt)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  24. Part 2 (MAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  25. Part 2 (MAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  26. Part 2 (MAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  27. Part 2 (MAD): Area under the plasma concentration-time curve from time zero to the dosing interval t concentration divided by the dose administered (Dose normalised AUCt)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  28. Part 2 (MAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  29. Part 2 (MAD): Ratio of the area under the curve (Rac AUC)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  30. Part 2 (MAD): Accumulation ratio based on Cmax (Rac Cmax)

    Time frame: Day 1 to Day 10

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  31. Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]

    Time frame: Day 1 and Day 8

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  32. Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine (Aeinf)

    Time frame: Day 1 and Day 8

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  33. Part 2 (MAD): Renal clearance of drug from plasma (CLR) assessed in urine

    Time frame: Day 1 and Day 8

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

  34. Part 3 (Bioavailability): Cmax of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  35. Part 3 (Bioavailability): tmax of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  36. Part 3 (Bioavailability): λz of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  37. Part 3 (Bioavailability): t½λz of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  38. Part 3 (Bioavailability): AUC(0-12) of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  39. Part 3 (Bioavailability): AUC(0-24) of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  40. Part 3 (Bioavailability): AUClast of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  41. Part 3 (Bioavailability): AUCinf of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  42. Part 3 (Bioavailability): CL/F of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  43. Part 3 (Bioavailability): Vz/F of AZD6793 (test Vs reference formulation)

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  44. Part 3 (Bioavailability) :Relative bioavailability calculated as test AUC/reference AUC [Frel AUC]

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  45. Part 3 (Bioavailability): Relative bioavailability calculated as test Cmax/reference Cmax [Frel Cmax]

    Time frame: Day 1 to Day 3

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

  46. Part 3 (Food effect): Cmax of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  47. Part 3 (Food effect): tmax of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  48. Part 3 (Food effect): λz of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  49. Part 3 (Food effect): t½λz of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  50. Part 3 (Food effect): AUC(0-12) of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  51. Part 3 (Food effect): AUC(0-24) of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  52. Part 3 (Food effect): AUClast of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  53. Part 3 (Food effect): AUCinf of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  54. Part 3 (Food effect): CL/F of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  55. Part 3 (Food effect): Vz/F of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  56. Part 3 (Food effect) :Frel AUC of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  57. Part 3 (Food effect): Frel Cmax of AZD6793 (under fasted and fed state)

    Time frame: Day 1 to Day 3

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

  58. Part 4 (COPD): Maximum observed plasma (peak) drug concentration (Cmax)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  59. Part 4 (COPD): Concentration at the end of the dosing interval (Ctrough)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  60. Part 4 (COPD): Temporal change parameter (TCP) assessed in urine

    Time frame: Day 1 and Day 8

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  61. Part 4 (COPD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  62. Part 4 (COPD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  63. Part 4 (COPD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  64. Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  65. Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  66. Part 4 (COPD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  67. Part 4 (COPD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  68. Part 4 (COPD): Area under plasma concentration time curve in the dosing interval t (AUCt)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  69. Part 4 (COPD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  70. Part 4 (COPD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  71. Part 4 (COPD): Ratio of the area under the curve (Rac AUC)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

  72. Part 4 (COPD): Accumulation ratio based on Cmax (Rac Cmax)

    Time frame: Day 1 to Day 28

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 22, 2022
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.